NNVC 1.42 ▲ 1.43% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    NanoViricides Inc.

    AMEX: NNVC · Real-Time Price · USD
    1.42
    0.02 (1.43%)
    At close: Sep 26, 2025, 3:59 PM
    1.42
    0.00%
    After-hours: Sep 26, 2025, 06:06 PM EDT
    1.43%
    Bid 1.4
    Market Cap 22.82M
    Revenue (ttm) n/a
    Net Income (ttm) -9.73M
    EPS (ttm) -0.69
    PE Ratio (ttm) -2.06
    Forward PE -1.29
    Analyst n/a
    Dividends n/a
    Ask 1.42
    Volume 40,880
    Avg. Volume (20D) 200,565
    Open 1.40
    Previous Close 1.40
    Day's Range 1.40 - 1.42
    52-Week Range 0.94 - 1.92
    Beta 1.15
    Ex-Dividend Date n/a

    About NNVC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NNVC
    Website n/a
    Full Company Profile
    2 months ago
    +14.29%
    NanoViricides shares are trading higher after the ... Unlock content with Pro Subscription
    4 months ago
    +7.63%
    NanoViricides shares are trading higher after the company announced it has been cleared by the DRC Ethics Committee to file a Phase II trial application for oral NV-387.
    news image

    2 weeks ago · accessnewswire.com

    RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

    This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical st...

    news image

    1 month ago · proactiveinvestors.com

    NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

    NanoViricides (NYSE-A:NNVC) said on Monday that its experimental broad-spectrum antiviral drug NV-387, now advancing into Phase II clinical trials, may help lower the risk of metastatic cancer returni...

    news image

    1 month ago · accessnewswire.com

    A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

    SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the deve...

    news image

    1 month ago · proactiveinvestors.com

    NanoViricides says antiviral candidate NV-387 could address global measles surge

    NanoViricides (NYSE-A:NNVC) said on Wednesday that its antiviral candidate NV-387 could play a key role in addressing the growing number of measles cases globally, particularly in industrialized natio...

    news image

    1 month ago · accessnewswire.com

    Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

    SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of bro...

    news image

    2 months ago · proactiveinvestors.com

    NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

    NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in g...

    news image

    2 months ago · accessnewswire.com

    NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

    SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the developm...

    news image

    2 months ago · proactiveinvestors.com

    NanoViricides says lead antiviral boosted survival in measles-infected mice

    NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based...

    news image

    2 months ago · accessnewswire.com

    Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

    SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of b...

    news image

    2 months ago · proactiveinvestors.com

    NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

    NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization's recent extension of the Public Health Emergency of International Concern (PH...

    Add to Watchlist